Circulating CD137⁺Treg cells and LOX-1⁺PMN-MDSCs as biomarkers of immunotherapy resistance in (R/M) HNSCC patients
The levels of blood circulating LOX-1⁺PMN-MDSCs may be proposed as non-invasive biomarkers to predict clinical outcomes of (R/M) HNSCC patients developing resistance to immunotherapy, improving patient selection and suggesting novel personalized therapies.
Authors
- Andrea Ballario
- Alessio Cirillo (ORCID: https://orcid.org/0000-0003-0449-9569)
- Francesco Valentino (ORCID: https://orcid.org/0000-0003-2016-4347)
- Chiara Napoletano (ORCID: https://orcid.org/0000-0001-5449-5430)
- Andrea Botticelli (ORCID: https://orcid.org/0000-0002-6425-9893)
- Ilaria Grazia Zizzari (ORCID: https://orcid.org/0000-0001-8263-7248)
- Marianna Nuti (ORCID: https://orcid.org/0000-0003-1809-1003)
- Angelica Pace (ORCID: https://orcid.org/0000-0003-2097-7874)
- Aurelia Rughetti (ORCID: https://orcid.org/0000-0002-1863-8251)
- Lidia Strigari (ORCID: https://orcid.org/0000-0003-4293-2298)
- Daniele Santini (ORCID: https://orcid.org/0000-0002-9118-3337)
- Angela Asquino (ORCID: https://orcid.org/0000-0001-8048-249X)
- Lucrezia Tuosto
Institutions
- Policlinico Umberto I (IT)
- Azienda USL di Bologna (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1186/s13046-025-03574-6
- Citations
- 2
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.59
Funders
- European Commission
- Sapienza Università di Roma